NCM · Biotechnology

Allarity Therapeutics, Inc. (ALLR) Stock

$0.99 +0.82% NCM: ALLR Healthcare

Valuation

MetricValue
Price$0.99
Market Cap$15.75M
P/E Ratio-1.33
P/B Ratio4.68
P/S Ratio47.96
EPS (TTM)$-0.78
52-Week High$1.84
52-Week Low$0.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-152.77%
ROA-38.41%
ROCE-305.29%
Gross Margin1.08%
Operating Margin-35.53%
Net Margin-32.61%
Debt/Equity6.30
Current Ratio2.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-27.0M$-34.0M$-17.0M$-27.0M$-13.0M
Net Profit$-27.0M$-16.0M$-12.0M$-25.0M$-11.0M
EPS$-79074.18$-31799.09$-6031.31$-15.79$-0.78
Op Margin————-3939.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$50.0M$15.0M$12.0M$23.0M$18.0M
Total Liabilities$31.0M$13.0M$15.0M$11.0M$8.0M
Cash$20.0M$2.0M$0$20.0M$15.0M
Borrowings$1.0M$4.0M$1.0M$1.0M$1.0M

Latest News

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration GlobeNewswire · Jul 7, 2026 Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year? Zacks · Jul 6, 2026 Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic GlobeNewswire · Jun 30, 2026 Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? Zacks · Jun 19, 2026 Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-17.0M$-13.0M$-17.0M$-15.0M
Investing Cash Flow$1.0M$1.0M$0$-1.0M$0
Financing Cash Flow$1.0M$-1.0M$2.0M$-3.0M$-3.0M
Net Cash Flow$19.0M$-18.0M$-2.0M$19.0M$-5.0M
Free Cash Flow$-15.0M$-17.0M$-13.0M$-18.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-1.97
FCF Yield-83.29%
Quick Ratio1.11
Interest Coverage-10.15
Return 1Y16.83%
Return 3Y-99.93%
Return 5Y—

Ownership

Insiders Held4.19%
Institutions Held5.98%
Institutions Float Held6.24%
Institutional HolderSharesReport Date
Renaissance Technologies, LLC228,0842026-03-31
Geode Capital Management, LLC190,3932026-03-31
Vanguard Capital Management LLC171,7952026-03-31
State Street Corporation137,6002026-03-31
Vanguard Fiduciary Trust Co74,9132026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCTXBriaCell Therapeutics Corp. $3.91 -0.26% -0.33 $34.02M 0.00%
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CINGCingulate Inc. $4.89 +0.20% -0.95 $65.86M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%
CRISCuris, Inc. $0.67 -5.38% -0.06 $1.31M 0.00%

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is led by CEO Thomas H. Jensen, employs 6 people, headquartered in US, publicly traded since 2021.

Allarity Therapeutics, Inc. (ALLR) stock trades at $0.99 with a market capitalization of $15.75M. The stock is valued at a price-to-earnings (P/E) ratio of -1.33, price-to-book of 4.68, price-to-sales of 47.96. Over the past 52 weeks the stock has ranged between $0.77 and $1.84, and currently trades 46.2% below its 52-week high.

On profitability, Allarity Therapeutics, Inc. generates a return on equity (ROE) of -152.77%, return on capital employed of -305.29%, an operating margin of -35.53%, a net profit margin of -32.61%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides